Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vimseltinib in chronic GVHD
NCT06619561Phase 2Recruiting
- Sponsor
- Deciphera Pharmaceuticals
- Start
- Nov 2024
- Primary completion
- Oct 2029
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vimseltinib in chronic graft-versus-host disease (cGVHD), sponsored by Deciphera Pharmaceuticals. Primary endpoints: Dose-Limiting Toxicities at 28 days and Adverse Events and Serious Adverse Events at 24 months. Started Nov 2024; status: recruiting.
02
Drugs
vimseltinib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT06619561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06619561.